NCT06415175Active, not recruiting
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
Prospective, Observational, Longitudinal Study in Paediatric Patients With AD, Treated With Dupilumab in Spain
Source: ClinicalTrials.gov · Last updated 25 Feb 2026
Brief summary (registry, in English)
This is a multicentre, prospective, non-interventional study that aims to describe the treatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in Spain: patients' characteristics, disease characteristics, prior treatments for and treatment prescription modalities. As well as to document the real-world effectiveness and safety of dupilumab during the two years of follow up. No diagnostic or therapeutic intervention outside of routine clinical practice will be applied.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 143 (actual)
- First submitted
- 10 May 2024
- Start date
- 14 Nov 2024
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Sanofi
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06415175
What you commit to
- Study type: Observational
- Participants enrolled: 143
- From 14 Nov 2024 to the primary completion date, 30 Sept 2026
- 15 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who are participating in an interventional clinical trial that modifies patient care.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Who the study is looking for
- Male or female aged 6 months to 11 years old at baseline.
- Patients with severe Atopic dermatitis (AD) according to the investigator's assessment.
- Patients initiating dupilumab (in those patients initiated retrospectively 2 months before the start of the study, the baseline information must be correctly filled out in the medical records).
- Signed informed consent by the parent/legally acceptable representative and assent by the patient appropriate to the patient's age.
Age in the registry: 6 months to 11 years · Sex: All · Does not accept healthy volunteers
Sites (15)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.